15. September 2022

Successful ISO9001:2015 recertification



Zedira has been recertified according to ISO 9001:2015 The new certificate is valid until September 12th, 2025.

Download Certificate
ISO9001Certificate-english.pdf (English Version)
ISO9001Zertifikat-deutsch.pdf (German Version)

Zedira is a provider of raw materials and is commitment to continually improving its products and services. The internationally recognized standard ISO 9001:2015 ensures Zedira’s products and services meet the needs of customers through an effective quality management system.

To become ISO 9001:2015 compliant, the entire Darmstadt (Germany) based Zedira team, underwent an extensive company-wide audit by TÜV Hessen. The certificate was first presented on September 13th, 2019 with the scope “research, development, production, and distribution in the area of biotechnology”. In 2022, our continuous efforts to further improve the quality management system has been acknowledged by the successful recertification.

Document

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • imageSuccessful ISO9001:2015 recertification
  • Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of non-alcoholic fatty liver disease (NAFLD)
  • Zedira publication - Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease
  • Dr. Falk Pharma and Zedira announce start of the phase 2b real-life study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie
  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis

Blog  

  • DZG Aktuell: „Aufruf zur Teilnahme an einer weiteren Wirksamkeitsstudie mit dem Studienmedikament ZED1227“
  • imageDesign of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
  • imageMicrobial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering

Events

  • 19th International Celiac Disease Symposium

    19.10.2022 - 22.10.2022
    Sorrento, Italy